Neupro Shortage Update: What Patients Need to Know in 2026

If you use Neupro (rotigotine transdermal patch) for Parkinson's disease or Restless Legs Syndrome, you may be wondering whether there is a current shortage in 2026 and what it means for your ability to fill your prescription. This post provides the most up-to-date information on Neupro's availability status, the history of its supply disruptions, and practical steps you can take as a patient to protect your access to this medication.

Is Neupro on the FDA Shortage List in 2026?

As of 2026, Neupro is not listed on the FDA's official drug shortage database. The FDA defines a drug shortage as a period when the supply of a drug is inadequate to meet the demand of patients and healthcare providers. The absence of Neupro from this list means there is no FDA-confirmed, nationwide manufacturing or distribution crisis for the medication.

However — and this is important — not being on the FDA shortage list does not mean Neupro is easy to find at every pharmacy. The FDA list reflects national supply, not local pharmacy stock. Neupro's brand-only status (no generic available) and its six-strength product line mean that any given pharmacy may be out of your specific dose even when the drug is technically available nationally.

Neupro Shortage History: What Happened in the Past

Neupro has a notable supply disruption history. In 2008, the European Medicines Agency (EMA) recommended recalling all batches of Neupro in Europe after microscopic crystals — resembling snowflakes — were discovered forming on the drug matrix layer of the patch. These crystals, which could cover up to 40% of the patch surface, raised concerns about whether patients were receiving their full intended dose of rotigotine.

As a result, Neupro's storage conditions were changed from room temperature to a cold-chain requirement (2°C–8°C storage), and the patches were reformulated. This disruption affected the European supply and led to temporary shortages in multiple EU countries. The FDA and US market were also impacted, as UCB voluntarily withdrew Neupro from the US market in 2008. The drug was re-approved for the US in 2012 with the revised cold-storage requirements built into the supply chain.

This history is relevant because it shows that Neupro's manufacturing and supply chain is more complex than typical oral medications. The transdermal patch format, the cold-chain handling requirements, and the product's brand-only status all make it more vulnerable to supply disruptions than generic oral alternatives like pramipexole or ropinirole.

Why Patients Experience Local Shortages Even Without an FDA Shortage

Even with no active nationwide shortage, many patients experience localized shortages for a few key reasons:

• Brand-only, high-cost inventory: At $873–$1,095 per 30-patch supply, Neupro is expensive to stock. Pharmacies order less to avoid tying up capital.
• Six separate strengths: Each of the 1 mg, 2 mg, 3 mg, 4 mg, 6 mg, and 8 mg strengths is a separate SKU. Your specific dose may be out while others are in stock.
• Single-source supply: UCB is the sole manufacturer. Any production hiccup at their facilities — even minor — has no backup supplier.
• Geographic distribution gaps: Smaller or rural pharmacies may not have regular ordering relationships for specialty medications like Neupro.

How to Protect Your Supply of Neupro in 2026

Patients on chronic Neupro therapy can take proactive steps to avoid running short:

1. Request 90-day supplies when possible. Mail-order pharmacies typically have more reliable access to brand-name drugs and fill 90-day supplies.
2. Refill 7–10 days before your supply runs out. This buffer gives you time to locate stock at another pharmacy if your usual one is out.
3. Use medfinder to locate stock efficiently. Instead of calling every pharmacy yourself, medfinder contacts pharmacies near you and texts you which ones can fill your prescription.
4. Have your neurologist on speed dial. If you are going to run out, contact your prescriber immediately. They may be able to bridge you with an oral dopamine agonist or contact the pharmacy directly.
5. Discuss the UCB Patient Assistance Program with your doctor. If cost is making it harder to stay on Neupro, ask about the UCB savings card (eligible commercially insured patients may pay as little as $10/month) and the UCB Patient Assistance Program for uninsured or underinsured patients.

Signs a True Shortage May Be Developing

Watch for these warning signs that a broader shortage may be emerging: multiple pharmacies (both chains and independents) report being out of stock and unable to order; your mail-order pharmacy cannot fill your prescription; your neurologist is receiving calls from multiple patients unable to fill Neupro; or UCB issues a press release or FDA notification about a supply disruption. If any of these occur, contact your neurologist immediately and check the FDA Drug Shortage Database at accessdata.fda.gov.

The Bottom Line

There is no active FDA shortage for Neupro in 2026, but the drug's brand-only status and complex supply chain mean that localized unavailability is a real and common problem for patients. The best protection is planning ahead. medfinder can help you find which pharmacies near you currently have your Neupro strength in stock. For more context, read our posts on why Neupro is hard to find and alternatives to Neupro if a true shortage develops.